TCT-808 Comparison between Clopidogrel and the New Oral P2Y12 Inhibitors in the Treatment of Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention

Martino Pepe,Annagrazia Cecere,Osvaldo Burattini,Luca Amato,Alessandro Santo Bortone,Emanuela De Cillis,Alessandro Cafaro, Nicola Forzati,Francesco Giardinelli,Stefano Favale

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2018）

引用 0|浏览13

暂无评分

摘要

Dual antiplatelet therapy improves angiographic results of primary percutaneous coronary intervention (pPCI) in patients with STEMI. The new oral P2Y12 inhibitors (P2Y12-I) prasugrel and ticagrelor are the gold-standard drugs because of a faster and more intense effect when compared to clopidogrel.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要